These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 22044557

  • 1. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB.
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [Abstract] [Full Text] [Related]

  • 2. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial.
    Muscari A, Puddu GM, Santoro N, Serafini C, Cenni A, Rossi V, Zoli M.
    Clin Neuropharmacol; 2011 Feb; 34(4):141-7. PubMed ID: 21677574
    [Abstract] [Full Text] [Related]

  • 3. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
    N Engl J Med; 2006 Aug 10; 355(6):549-59. PubMed ID: 16899775
    [Abstract] [Full Text] [Related]

  • 4. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA.
    Stroke; 2014 Oct 10; 45(10):2974-82. PubMed ID: 25147328
    [Abstract] [Full Text] [Related]

  • 5. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators.
    Stroke; 2008 Dec 10; 39(12):3297-302. PubMed ID: 18845807
    [Abstract] [Full Text] [Related]

  • 6. Irbesartan in patients with atrial fibrillation.
    ACTIVE I InvestigatorsPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada., Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.
    N Engl J Med; 2011 Mar 10; 364(10):928-38. PubMed ID: 21388310
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby BM, Strandhave C, Jensen JD.
    Am J Kidney Dis; 2014 Dec 10; 64(6):892-901. PubMed ID: 25011693
    [Abstract] [Full Text] [Related]

  • 8. Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
    Lavallée PC, Labreuche J, Gongora-Rivera F, Jaramillo A, Brenner D, Klein IF, Touboul PJ, Vicaut E, Amarenco P, Lacunar-BICHAT Investigators.
    Stroke; 2009 May 10; 40(5):1721-8. PubMed ID: 19286582
    [Abstract] [Full Text] [Related]

  • 9. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis.
    Kidney Int; 2002 Apr 10; 61(4):1469-74. PubMed ID: 11918754
    [Abstract] [Full Text] [Related]

  • 10. STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
    Neilipovitz DT, Bryson GL, Taljaard M.
    Can J Anaesth; 2012 Jun 10; 59(6):527-37. PubMed ID: 22528165
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
    Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators.
    N Engl J Med; 2005 Jun 09; 352(23):2389-97. PubMed ID: 15944423
    [Abstract] [Full Text] [Related]

  • 12. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Marchione P, Vento C, Morreale M, Izzo C, Maugeri A, Manuppella F, Romeo T, Giacomini P.
    J Stroke Cerebrovasc Dis; 2015 Jan 09; 24(1):138-43. PubMed ID: 25440329
    [Abstract] [Full Text] [Related]

  • 13. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
    JAMA; 2001 Apr 04; 285(13):1711-8. PubMed ID: 11277825
    [Abstract] [Full Text] [Related]

  • 14. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators.
    Drugs; 2004 Apr 04; 64 Suppl 2():43-60. PubMed ID: 15765890
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial.
    Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, Bradley D, Cha YM, Brady PA, Munger TM, Asirvatham SJ, Packer DL, Friedman PA.
    Heart Rhythm; 2012 Feb 04; 9(2):172-8. PubMed ID: 21920481
    [Abstract] [Full Text] [Related]

  • 16. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.
    J Clin Endocrinol Metab; 2007 Dec 04; 92(12):4671-7. PubMed ID: 17726081
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 04; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M.
    Pharmacotherapy; 2011 Nov 04; 31(11):1045-50. PubMed ID: 22026392
    [Abstract] [Full Text] [Related]

  • 19. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
    Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS.
    Atherosclerosis; 2010 Nov 04; 213(1):218-24. PubMed ID: 20810109
    [Abstract] [Full Text] [Related]

  • 20. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects.
    Schindler C, Brosnihan KB, Ferrario CM, Bramlage P, Maywald U, Koch R, Oertel R, Kirch W.
    J Clin Pharmacol; 2007 Jan 04; 47(1):112-20. PubMed ID: 17192509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.